Drugs / NS2
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02578914 | Aug → Dec 2015 | conjunctivitis, seasonal allergic rhinitis | Aldeyra Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02402309 | Mar 2015 → May 2016 | Sjogren-Larsson syndrome | Aldeyra Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NS2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02402309 ↗ |
| Action | Inhibit | “decrease inflammation by lowering aldehyde levels” NCT02578914 ↗ |
| Modality | Small molecule | “NS2, a small molecule aldehyde trap” NCT02578914 ↗ |
| Route | Topical | “topically-applied NS2 dermatologic cream” NCT02402309 ↗ |